New FDA approval for Atezolizumab plus Cobimetinib and Vemurafenib for patients with BRAF V600-positive advanced melanoma! Find more information on this in CKB CORE. Need up-to-date information on other FDA drug approvals? Consider a CKB BOOST subscription, which includes full acess to all drugs and their FDA approvals, along with related content!
2020
May
Check out CKB's new cancer variant visual navigation! Learn more here.
2020
February
Check out this recent article to learn how CKB can be your genomic digital encyclopedia of cancer! Mainstreaming Precision Oncology
2020
January
CKB CORE now offers content for RSPO3, POLE, FANCA, and DOT1L, but removes EGFR, PTEN, TP53, and MET. However, these genes are always accessible with a CKB BOOST subscription!
2019
October
Have a question about CKB or want to learn more about it? Then check out The Scoop on CKB!
2019
September
We're looking for new people to join the CKB team! Check out the job listing here: Clinical Scientific Curator
2019
July
CKB BOOST now has AMP/CAP/ASCO evidence level coding!
2018
November
Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit ckbhome.jax.org and sign-up for CKB BOOST.
Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic (PMID: 28402162). Limited free copies available; request your copy at ckbsupport@jax.org.